Comparing Megestrol Acetate Therapy with Oxandrolone Therapy for HIV-Related Weight Loss: Similar Results in 2 Months

Mwamburi, D. Mkaya; Wilson, Ira B.; Chang, Hong; Scully, Ed; Saboori, Shiva; Miller, Laurel; Forfia, Janet; Albrecht, Mary; Wanke, Christine A.; Gerrior, Jül
March 2004
Clinical Infectious Diseases;3/15/2004, Vol. 38 Issue 6, p895
Academic Journal
Weight loss is known to impact survival among patients infected with human immunodeficiency virus (HIV) even in the era of highly active antiretroviral therapy (HAART). In a randomized trial, we compared the effects of 2 months of treatment with either megestrol acetate (800 mg every day) or oxandrolone (10 mg twice per day) on body weight and composition in patients with weight loss of ≥5 kg who were receiving HAART. The mean weight was 66 kg, and the mean body mass index was 21. Mean weight gain in the megestrol acetate and the oxandrolone arms were 2.8 kg (4.6% of the baseline value) and 2.5 kg (3.9% of the baseline value), respectively (P = .80 ). Lean body mass accounted for 39% of weight gain in the megestrol acetate arm and Pp.80 56% in the oxandrolone arm (P = .38 ). Seven patients in the megestrol acetate arm and 5 patients in the Pp.38 oxandrolone arm reported minor adverse events (P = .74 ). In conclusion, megestrol acetate therapy and Pp.74 oxandrolone therapy have similar effects on body weight and composition and are safe and well-tolerated during HAART.


Related Articles

  • Efavirenz/emtricitabine/tenofovir.  // Reactions Weekly;6/20/2009, Issue 1257, p19 

    The article describes the case of a 30-year-old woman who developed central nervous system (CNS) toxoplasmosis associated with immune reconstitution syndrome (IRS) during highly-active antiretroviral therapy (HAART) with efavirenz, tenofovir and emtricitabine for an HIV-1 infection. It discusses...

  • Adverse Drug Reactions Reported to a National HIV & Tuberculosis Health Care Worker Hotline in South Africa: Description and Prospective Follow-Up of Reports. Njuguna, Christine; Stewart, Annemie; Mouton, Johannes; Blockman, Marc; Maartens, Gary; Swart, Annoesjka; Chisholm, Briony; Jones, Jackie; Dheda, Mukesh; Igumbor, Ehimario; Cohen, Karen; Mouton, Johannes P; Igumbor, Ehimario U // Drug Safety;Feb2016, Vol. 39 Issue 2, p159 

    Introduction: The National HIV & Tuberculosis Health Care Worker (HCW) Hotline provides advice on the management of suspected adverse drug reactions (ADRs). We describe suspected ADRs reported to the hotline by HCWs, concordance with advice, and patient outcomes.Methods:...

  • In case of emergency. Burrell, James // Xtra (Toronto);10/11/2007, Issue 599, p10 

    The article focuses on the prescription of post-exposure prophylaxis (PEP) to individuals facing possible HIV-exposure in nonoccupational settings including condom breaks in Canada. The treatment is an emergency course of combined antiretroviral drugs believed to combat HIV infection. PEP must...

  • Antiretrovirals.  // Reactions Weekly;Nov2015, Vol. 1577 Issue 1, p41 

    The article presents a case study of a 52-year-old woman who developed avascular necrosis of the knee while receiving antiretroviral therapy for HIV.

  • Didanosine.  // Reactions Weekly;12/15/2007, Issue 1182, p14 

    The article describes the case of a 40-year-old man developed Fanconi's syndrome and nephrogenic diabetes insipidus during treatment with didanosine. The man is being treated for HIV infection. The symptoms presented by the patient include weight loss, fatigue and neurological aggravation. Based...

  • Olanzapine.  // Reactions Weekly;1/13/2007, Issue 1134, p21 

    The article presents a case study of a 57-year-old man with schizophrenia, who lost the weight he gained during olanzapine therapy. For four years olanzapine 10 grams/day was added to the man's psychiatric regimen to control his psychosis. Over this period he gained weight, increasing from 93.6...

  • Older Age When Starting Antiretrovirals Lowers Chance of Good CD4 Gain.  // HIV Treatment ALERTS!;Mar2011, p24 

    The article presents a study on the role of age when starting antiretrovirals in lowering the chances of gaining 100 CD4 cells in North America. The study found out that viral load response is not affected by age. According to the study, the effect of age on CD4 gains held true regardless of...

  • HIV: long-term management and palliative care. Rigg, Carolyn // InnovAiT;Sep2011, Vol. 4 Issue 9, p527 

    The advent of antiretroviral therapy has radically changed the prognosis of human immunodeficiency virus (HIV) infection. HIV is now a treatable medical condition and is increasingly managed as a chronic disease. The majority of those living with the virus remain fit and well on treatment....

  • Management of common adverse effects in the era of highly active antiretroviral therapy in south east Ethiopia. Abdella, Sadikalmahdi Hussen; Wabe, Nasir Tajure; Yesuf, Elias Ali // North American Journal of Medical Sciences;Nov2011, Vol. 3 Issue 11, p499 

    Background: The combination of antiretroviral therapy is the corner stone of management of patients with human immune deficiency virus infection. Although antiretroviral therapy can reduce viral load to undetectable level, improve the immunity and prolong survival of patients, antiretroviral...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics